Core Viewpoint - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is planning to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. for a total price of 334.85 million yuan, which includes both share issuance and cash payment [1][2]. Group 1: Transaction Details - The transaction price is set at 33,484.94 million yuan, with 30,105.88 million yuan paid in shares and 3,379.06 million yuan in cash [1]. - The company will issue 7,271,946 shares, representing 9.84% of the total share capital post-issuance (excluding supporting financing) [1]. Group 2: Funding and Purpose - The company plans to raise an additional 13,357.64 million yuan from its controlling shareholder Yuan Yuyu to supplement working capital, fund R&D projects, and cover cash payments [2]. - This restructuring aims to expand the company's presence in the neuro-interventional medical device sector, enhancing technological synergy and channel integration [2]. Group 3: Regulatory Aspects - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring or a restructuring listing [2]. - The transaction is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, indicating potential uncertainties in implementation [2].

本轮融资由高特佳领投，资金将加速推进公司产品的创新研发和商业化进程，为神经介入专家提供更优 的治疗方式。 近日，苏州无限医疗科技有限公司（Infinity Neuro）——一家专注为神经血管外科提供创新解决方案的 医疗器械公司宣布，已完成数亿元人民币的A轮融资。 无限医疗（Infinity Neuro）主要从事脑血管领域医疗器械的研发、生产和商业化，致力于与神经科医生 深入合作，聚焦神经介入领域未被满足的临床需求，产品覆盖治疗出血性和缺血性卒中的两大核心产品 线。核心团队均来自于跨国医疗器械公司，拥有多次成功创业经历，核心团队深度聚焦神经介入领域出 血性和缺血性卒中市场，具有神经介入医疗器械产品研发、临床、产业化及产品迭代升级的丰富经验。 ...